TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01640275

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: patients randomized to the propofol arm of the study will receive general anesthesia with propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane
Description: patients randomized to the isoflurane arm of the study will receive general anesthesia with isoflurane
Study: NCT04671134

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomimetic remineralizing agent
Description: Self-assempling peptide

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biomimetic remineralizing agent
Description: Self-assempling peptide

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resin Modified Glass Ionomer Varnish
Description: Resin Modified Glass Ionomer Varnish

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resin Modified Glass Ionomer Varnish
Description: Resin Modified Glass Ionomer Varnish
Study: NCT05350579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yogurt Intervention
Description: Participants will be asked to consume one serving of yogurt per day.~Nutrient composition of yogurt provided to participants in the yogurt group:~Nutrients per serving Serving Size: 141 g Energy (kcal) 170 Total Fat (g) 8 Total Carbohydrate (g) 16 Sugars (g) 15 Protein (g) 5 Sodium (mg) 85 Calcium (%) 15 Vitamin A (%) 4 Ingredients: Pasteurized Grade A Milk, Cane Sugar, Yogurt Cultures (S. thermophilus, L. bulgaricus), Vanilla Extract.
Study: NCT04270630

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared Decision Aid
Description: The decision aid was developed by this study group based on the International Patient Decision Aid Standards Collaboration's minimum standards for quality, and the Ottawa Framework (a process by which patients' and clinicians' decision determinants are assessed, a decision aid is developed that is tailored to these needs, and the quality of the decision-making process with the aid is evaluated). The aid then underwent an iterative feedback process with a patient advisory panel. Adjustments to format, length, and readability were made. A final feedback session occurred with three patients over the age of 70, after which point the paper decision aid was digitalized. The intervention will be delivered in-person by one of the co-investigators of the study. The intervention will occur once, prior to the patient making a final decision regarding undergoing left heart catheterization as treatment for NSTEMI. The approximate duration of the intervention is 30 minutes.
Study: NCT00001563

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Filgrastim after EPOCH-R from Day 6 for 10 days every cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: EPOCH-R every 3 weeks for up to 6 cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPOCH
Description: EPOCH-R every 3 weeks for up to 6 cycle
Study: NCT02425930

Intervention type: PROCEDURE
Intervention: gastrectomy plus D2 lymphadenectomy
Description: A classic total or subtotal gastrectomy plus D2 lymph nodes dissection would be performed for all enrolled patients. Patients in both groups would undergo the identical therapeutic approach for gastric cancer, mainly decided by a multidisciplinary treatment group in our center.

Intervention type: PROCEDURE
Intervention: gastrectomy plus D2 lymphadenectomy
Description: A classic total or subtotal gastrectomy plus D2 lymph nodes dissection would be performed for all enrolled patients. Patients in both groups would undergo the identical therapeutic approach for gastric cancer, mainly decided by a multidisciplinary treatment group in our center.

Intervention type: DRUG
Intervention: S-1+Oxaliplatin
Description: A postoperative systemic chemotherapy would be performed for some subjects who have advanced gastric cancer. The concrete chemo regimen for adjuvant chemotherapy is also determined by a MDT group. Generally, SOX chemo regimen is the first-line treatment in our center, as following described:~* S-1: 40\~60mg bid，po, Day1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid）~* Oxaliplatin: 130mg/m2，iv drip for 2h，Day1

Intervention type: DRUG
Intervention: S-1+Oxaliplatin
Description: A postoperative systemic chemotherapy would be performed for some subjects who have advanced gastric cancer. The concrete chemo regimen for adjuvant chemotherapy is also determined by a MDT group. Generally, SOX chemo regimen is the first-line treatment in our center, as following described:~* S-1: 40\~60mg bid，po, Day1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid）~* Oxaliplatin: 130mg/m2，iv drip for 2h，Day1
Study: NCT01906554

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Egg Dose
Description: Different quantities of eggs
Study: NCT02369445

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moisture Pager Intervention for Toilet Training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Study: NCT00002565

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bleomycin sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesna

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study: NCT04793802

Intervention type: OTHER
Intervention: PHYSIO
Description: session of physiotherapy
Study: NCT00938704

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboxymethylcellulose 0.5% +glycerin 0.9%
Description: To open, twist and pull tab to remove. Instill study medication as needed, but at least one drop 3 times a day as instructed in the protocol and then discard the container.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium hyaluronate 0.18%
Description: To open, twist and pull tab to remove. Instill study medication as needed, but at least one drop 3 times a day as instructed in the protocol and then discard the container.
Study: NCT04081103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexagon® (lufepirsen) High Dose Concentration
Description: Nexagon® (lufepirsen) is administered topically in the affected eye three (3) times over 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexagon® (lufepirsen) Low Dose Concentration
Description: Nexagon® (lufepirsen) is administered topically in the affected eye three (3) times over 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle is administered topically in the affected eye three (3) times over 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open-label Nexagon® (lufepirsen)
Description: Open-label Nexagon® (lufepirsen) for participants who do not heal (re-epithelialize) at the end of the 28-day treatment phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open-label Nexagon® (lufepirsen)
Description: Open-label Nexagon® (lufepirsen) for participants who do not heal (re-epithelialize) at the end of the 28-day treatment phase.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Open-label Nexagon® (lufepirsen)
Description: Open-label Nexagon® (lufepirsen) for participants who do not heal (re-epithelialize) at the end of the 28-day treatment phase.
Study: NCT02582775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: 0.5 mg/kg IV over 6 hours on day -9 and 2 mg/kg IV over 4 hours on day -8 and day -7 with premeds and solumedrol through day -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: 0.5 mg/kg IV over 6 hours on day -9 and 2 mg/kg IV over 4 hours on day -8 and day -7 with premeds and solumedrol through day -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: 0.5 mg/kg IV over 6 hours on day -9 and 2 mg/kg IV over 4 hours on day -8 and day -7 with premeds and solumedrol through day -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: 0.5 mg/kg IV over 6 hours on day -9 and 2 mg/kg IV over 4 hours on day -8 and day -7 with premeds and solumedrol through day -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: 0.5 mg/kg IV over 6 hours on day -9 and 2 mg/kg IV over 4 hours on day -8 and day -7 with premeds and solumedrol through day -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: 0.5 mg/kg IV over 6 hours on day -9 and 2 mg/kg IV over 4 hours on day -8 and day -7 with premeds and solumedrol through day -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: 0.5 mg/kg IV over 6 hours on day -9 and 2 mg/kg IV over 4 hours on day -8 and day -7 with premeds and solumedrol through day -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: 0.5 mg/kg IV over 6 hours on day -9 and 2 mg/kg IV over 4 hours on day -8 and day -7 with premeds and solumedrol through day -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 14.5 mg/kg IV over 1 hour day -6 and -5 50 mg/kg IV over 2 hours with mesna 40 mg/kg IV day +2 and +3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 14.5 mg/kg IV over 1 hour day -6 and -5 50 mg/kg IV over 2 hours with mesna 40 mg/kg IV day +2 and +3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 14.5 mg/kg IV over 1 hour day -6 and -5 50 mg/kg IV over 2 hours with mesna 40 mg/kg IV day +2 and +3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 14.5 mg/kg IV over 1 hour day -6 and -5 50 mg/kg IV over 2 hours with mesna 40 mg/kg IV day +2 and +3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 14.5 mg/kg IV over 1 hour day -6 and -5 50 mg/kg IV over 2 hours with mesna 40 mg/kg IV day +2 and +3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 14.5 mg/kg IV over 1 hour day -6 and -5 50 mg/kg IV over 2 hours with mesna 40 mg/kg IV day +2 and +3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 14.5 mg/kg IV over 1 hour day -6 and -5 50 mg/kg IV over 2 hours with mesna 40 mg/kg IV day +2 and +3
Study: NCT04217590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate
Description: Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of SZC 5g depending on dose level assigned to a patient per non-dialysis days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of Placebo depending on dose level assigned to a patient per non-dialysis days.
Study: NCT00860613

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medical nutrition therapy program
Description: the dietary guidelines were based on the Nutrition Practice guidelines for gestational diabetes developed by the American Dietetic Association. Dietary strategies were based on carbohydrate counting and/or restriction of high glycemic index foods. Even carbohydrate distribution throughout the day was emphasized.
Study: NCT02582775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 14.5 mg/kg IV over 1 hour day -6 and -5 50 mg/kg IV over 2 hours with mesna 40 mg/kg IV day +2 and +3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2 IV over 60 minutes days -6 through day -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2 IV over 60 minutes days -6 through day -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2 IV over 60 minutes days -6 through day -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2 IV over 60 minutes days -6 through day -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2 IV over 60 minutes days -6 through day -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2 IV over 60 minutes days -6 through day -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2 IV over 60 minutes days -6 through day -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2 IV over 60 minutes days -6 through day -2

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: See arm description for dosing.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: See arm description for dosing.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: See arm description for dosing.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: See arm description for dosing.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: See arm description for dosing.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: See arm description for dosing.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: See arm description for dosing.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: See arm description for dosing.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow infusion
Description: Bone marrow infusion on Day 0

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow infusion
Description: Bone marrow infusion on Day 0

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow infusion
Description: Bone marrow infusion on Day 0
Study: NCT04294732

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: bupivacaine is a local anesthetic drug which is already using in surgical procedures.~saline is isotonic solution of which has include %0,9 NACL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: bupivacaine is a local anesthetic drug which is already using in surgical procedures.~saline is isotonic solution of which has include %0,9 NACL.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Only spinal anesthesia without peripheral nerve block
Description: Only spinal anesthesia without peripheral nerve block
Study: NCT02594826

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally appropriate intervention
Description: Church-based educational intervention combined with navigation assistance

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General health education control
Description: General health and cancer education
Study: NCT01321346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Dose will be assigned at study entry. Patients will take panobinostat orally 3 times a week given on a Monday, Wednesday, Friday schedule, every week. One course is 28 days (4 weeks). Patients will get 2 courses and may receive up to 8 courses total.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: All patients will receive 70 mg of intrathecal cytarabine on day 0 of course 1. The day 0 dose must be given at least 24 hours prior to initiation of panobinostat. Omit the day 0 dose of intrathecal cytarabine if the patient received intrathecal therapy within 72 hours of treatment.~All patients will receive 70 mg of intrathecal cytarabine on day 29 of course 1-8 in conjunction with their disease evaluation.
Study: NCT03217071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: All study participants will receive pembrolizumab every 3 weeks, for 2 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: All study participants will receive pembrolizumab every 3 weeks, for 2 cycles.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiation therapy (SRT)
Description: Patients in Cohort 2 of the Safety run-in and patients in the expansion cohort who are randomized to the 'pembrolizumab +radiation arm' will receive one dose of SRT within 1 week (+/- 3 days) following the second administration of pembrolizumab.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery (Non-interventional, standard of care)
Description: Standard of care surgery to remove cancer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery (Non-interventional, standard of care)
Description: Standard of care surgery to remove cancer
Study: NCT04817163

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based cognitive-behavioral therapy for insomnia (CBT-I)
Description: Each week, the patients first have to read written information on the website (www.insomnet.ca), and then watch a video capsule (duration between 5 and 20 min each). Patients complete their daily sleep diary electronically on the website and the content is interactive. It includes the sending of automated emails to remind participants to complete the treatment tasks and encourage adherence, provision of tailored feedback (e.g., texts, charts) based on the information that they provide in their sleep diary, as well as quizzes with automated correction to reinforce patients' understanding of the content.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Professionally-administered booster face-to-face CBT-I sessions
Description: Patients who obtain an ISI score of 8 and more after completing the web-based CBT-I are stepped up and offered to receive up to three 50-min booster sessions of CBT-I offered individually by a psychologist (if needed). Remitted patients (good sleepers; ISI score lower than 8) will receive no further treatment.
Study: NCT01321346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Dose will be assigned at study entry. Patients will take panobinostat orally 3 times a week on a Monday, Wednesday, Friday schedule, every other week. Once course is 28 days (4 weeks). Patients will get 2 course and may receive up to 8 courses of therapy.
Study: NCT02254525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous ibuprofen
Description: Treatment group: 800 mg IV ibuprofen, starting at the moment of skin closure and every 6 hours up to 72 hours after the first dose.~All patients will receive morphine administered by patient controlled analgesia (PCA). Investigation treatment will be administered every 6 hours until 24 h in abdominal surgery, 48 h in hip surgery and 72 h in knee surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Placebo group: 200 ml of saline solution, starting at the moment of skin closure and every 6 hours up to 72 hours after the first dose.~All patients will receive morphine administered by patient controlled analgesia (PCA). Investigation treatment will be administered every 6 hours until 24 h in abdominal surgery, 48 h in hip surgery and 72 h in knee surgery.
Study: NCT01285050

Intervention type: DRUG
Group type: OTHER
Intervention: Antiretroviral therapy (ART)
Description: Peginterferon alfa-2b administered once as part of a pharmacokinetic study before and after anti-HIV medications. Peginterferon is used to produce a measurement but the intervention is the HIV medications which are specified as raltegravir, emtricitabline, and tenofovir disoproxil fumerate.

Intervention type: DRUG
Group type: OTHER
Intervention: raltegravir
Description: raltegravir is an HIV medication given 400 mg twice daily by mouth

Intervention type: DRUG
Group type: OTHER
Intervention: Emtricitabine and tenofovir disoproxil fumarate
Description: Emtricitabine and tenofovir disoproxil fumarate are HIV medications, combination pill, once per day by mouth
Study: NCT01498289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: Given IV. Fluorouracil, oxaliplatin, \& leucovorin calcium.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 30 mg/m\^2, IV over 30 minutes on Day 1,8 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: 400 mg/m\^2, IV bolus on Day 1 of each 14 day cycle; 2400 mg/m\^2 IV over 46-48 hours on Days 1-2 of each 14 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: 65 mg/m\^2, IV over 90 minutes on Days 1 \& 8 of every 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: 400 mg/m\^2, IV over 2 hours on Day 1 of every 14 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 85 mg/m\^2, IV over 2 hours on Day 1 of every 14 day cycle.
Study: NCT06135675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2092 capsules
Description: TNP-2092 capsules will be orally administered 30 min after breakfast and dinner for 14 consecutive days, and last dose will be administered 30 min after breakfast on the morning of D15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2092 capsules
Description: TNP-2092 capsules will be orally administered 30 min after breakfast and dinner for 14 consecutive days, and last dose will be administered 30 min after breakfast on the morning of D15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2092 capsules
Description: TNP-2092 capsules will be orally administered 30 min after breakfast and dinner for 14 consecutive days, and last dose will be administered 30 min after breakfast on the morning of D15.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TNP-2092 capsules Placebo
Description: TNP-2092 capsules Placebo will be orally administered 30 min after breakfast and dinner for 14 consecutive days, and last dose will be administered 30 min after breakfast on the morning of D15.
Study: NCT01146626

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg+ Vitamin D+ Ribavirine
Description: Peg+ Vitamin D+ Ribavirine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg+ Ribavirine
Description: Peg+ Ribavirine